Revenue
2021
2022
2023
Phaxiam Therapeutics (PHXM)
Price—Loading quote
Financial statements
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Revenue | €1.3M | €31.0M | €4.2M |
| Research & development | €10.9M | €19.9M | €45.1M |
| Operating expenses | €25.0M | €33.8M | €60.7M |
| Operating income | −€23.7M | −€2.8M | −€56.5M |
| Operating margin | −1,784.31% | −9.02% | −1,352.03% |
| EBITDA | −€22.9M | €1.8M | −€51.1M |
| EBITDA margin | −1,724.51% | 5.88% | −1,223.40% |
| Net income | −€23.5M | −€228,000 | −€53.8M |
| Net profit margin | −1,771.34% | −0.74% | −1,287.01% |
| Basic EPSper basic share | -€5.00 | -€0.07 | -€22.71 |
| Diluted EPSper diluted share | -€5.00 | -€0.07 | -€22.71 |
Owners
Reported shareholders and owner groups
10.73%of company shares
Auriga BioseedsSource updated Jan 23, 2025
View holders
| Holder | Ownership |
|---|---|
| 10.73%Jan 23, 2025 | |
| 7.77%Jan 23, 2025 | |
| 7.34%Jan 23, 2025 | |
| 3.58%Jan 23, 2025 | |
| 3.39%Jan 23, 2025 | |
| 1.68%Jan 23, 2025 | |
| 0.12%Jan 23, 2025 | |
| 0.03%Jan 23, 2025 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026